RECRUITING

OnabotulinumtoxinA for Trigeminal Neuralgia

Description

A randomized controlled trial comparing Onabotulinumtoxin A to saline (placebo) for Trigeminal Neuralgia.

Conditions

Trigeminal Neuralgia
Talk to us

Related Conditions:

Trigeminal Neuralgia

Study Overview

On this page

Study Details

Study overview

A randomized controlled trial comparing Onabotulinumtoxin A to saline (placebo) for Trigeminal Neuralgia.

Randomized Controlled Trial of Intradermal Injections of OnabotulinumtoxinA vs Saline for Trigeminal Neuralgia.

OnabotulinumtoxinA for Trigeminal Neuralgia

Condition
Trigeminal Neuralgia
Intervention / Treatment

-

Contacts and Locations

Stanford

Meredith Barad, Stanford, California, United States, 94304

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Judged to be of legal competence
  • * Sufficient knowledge of written and spoken English
  • * Capable of attending regular in-person visits
  • * Have failed/not a candidate/do not want surgery
  • * Inadequate response to medication - at least 2 trials
  • * Meeting ICHD criteria for Classical Trigeminal Neuralgia 13.1.1.1
  • * Patients with frequency \> 10 attacks per week
  • * Stable dose of medications in the last 2 weeks
  • * Secondary or Idiopathic TN, or Painful Trigeminal Neuropathy as defined by the ICHD (13.1.1.2, 13.1.1.3, 13.1.2)
  • * Pregnant or breast feeding (while it is rare that a patient will be pregnant with TN, there is not sufficient data to say definitively that onabotA is ok to use during pregnancy and nursing, it is still rated Class C)
  • * Neuromuscular disease
  • * On aminoglyocosides
  • * Not currently enrolled in any other studies

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Stanford University,

Meredith Barad, MD, PRINCIPAL_INVESTIGATOR, Stanford University

Study Record Dates

2025-09-01